Stage set to determine if drugs called tyrosine kinase inhibitors will extend the lives of patients with the high-risk acute lymphoblastic leukemia subtype; pediatric clinical trial scheduled to open by early 2015
More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. Jude Children’s Research Hospital investigators. The study appears in the current issue of The New England Journal of Medicine.
ALL is the most common childhood cancer. The research focused on a subtype of ALL known as Philadelphia chromosome-like ALL (Ph-like ALL). In 2009, St. Jude scientists, working with the Children’s Oncology Group (COG), were among the first to describe the Ph-like ALL subtype in children. The present study found the prevalence of Ph-like ALL increases with age and that the subtype is associated with poor survival. The discovery followed a detailed genomic analysis of 1,725 patients ages 1 to 39 with the most common form of ALL, which involves white blood cells known as B cells and is called B-ALL.
Researchers also used next-generation sequencing to identify the genetic alterations that give rise to Ph-like ALL, including some involving genes not previously linked to cancer. The results highlight the genetic diversity of Ph-like ALL, but also demonstrate that alterations affect a limited number of biological signaling pathways. Those pathways regulate genes controlling cell growth and proliferation, which are disrupted in cancer.
The findings, combined with earlier work from St. Jude and other institutions, laid the foundation for clinical trials to determine whether drugs called tyrosine kinase inhibitors (TKIs) could help improve patient outcomes. A nationwide study meant to answer that question in children is scheduled to begin later this year or early in 2015. By targeting enzymes known as kinases, TKIs work more precisely than chemotherapy drugs to kill cancer cells.
“We showed that Ph-like ALL is a common disease that spans the age spectrum, and we identified new genomic alterations that converge on a handful of signaling pathways that are vulnerable to treatment with tyrosine kinase inhibitors,” said corresponding author Charles Mullighan, M.D., MBBS(Hons), a member of the St. Jude Department of Pathology. “The findings lead the way for clinical trials that could help to transform the outlook for patients regardless of age.”
TKIs, including drugs like dasatnib and imatinib, are widely used to treat other types of leukemia that are more common in adults. The drugs have also been used in a small number of patients with Ph-like ALL. This study reports the experiences of eight such patients, including seven children who were treated at different medical centers. All had leukemia that persisted despite chemotherapy. Each patient enjoyed a dramatic, immediate benefit when a TKI was added to the treatment regime. Five patients remain in remission with no detectable cancer, one for more than a year.
“The findings are tremendously exciting and pave the way for clinical trials testing TKIs plus chemotherapy in subsets of children and adolescents with ALL,” said corresponding author Stephen P. Hunger, M.D., professor of pediatrics at the University of Colorado School of Medicine and the chair of the COG ALL Committee. Investigators from the COG and St. Jude have developed plans to test more than 800 children annually enrolled in COG ALL clinical trials to identify those who might benefit from this treatment approach. That is the clinical trial expected to open this year or early in 2015.
Ph-like ALL is named for a chromosomal rearrangement known as the Philadelphia (Ph) chromosome, which is associated with a different subtype of ALL. Both Ph-positive and Ph-like subtypes of ALL share similar patterns of gene expression, but patients with Ph-like ALL lack the fusion of the BCR and ABL1 genes that is a feature of Ph-positive ALL.
In this study, Ph-like ALL comprised 10 percent of children 1 to 9 years old with standard-risk B-ALL. The percentage rose with age and accounted for 27 percent of B-ALL cases among those ages 21 to 39. Work is underway to establish the incidence in older adults.
Regardless of their age, patients with Ph-like ALL were less likely than other B-ALL patients to be alive and cancer free five years after their disease was discovered. Overall survival for children, adolescents and young adults with Ph-like ALL was 62 percent compared to 91 percent for other B-ALL patients of the same age. Leukemia-free survival was about 47 percent for patients with Ph-like ALL and about 83 percent for other patients.
The search for the genetic changes that give rise to Ph-like ALL included whole genome sequencing of 42 patients plus additional sequencing, including of RNA from the leukemic cells of 136 patients. The genome is the complete set of instructions needed to assemble and sustain life. It is encoded in the DNA molecule carried in almost every cell. RNA sequencing provides a snapshot of gene activity in cells.
Researchers found that 91 percent of patients with Ph-like ALL had chromosomal rearrangements or other genetic alterations that activate cytokine receptor or kinase signaling. An analytic tool called CICERO, which was developed by St. Jude researchers, played a key role in identifying the changes. Kinases are enzymes that serve as on-off switches in cells. Cytokine receptors regulate how cells respond to growth factors called cytokines.
“We identified several new subgroups of Ph-like ALL that were distinguished by the type of cytokine receptor or kinase gene alteration,” said Kathryn Roberts, Ph.D., a St. Jude postdoctoral fellow. She and Yongjin Li, Ph.D., a St. Jude Department of Computational Biology research scientist, are the paper’s co-first authors.
Evidence suggests that several of the newly identified Ph-like ALL subtypes are vulnerable to TKIs and other targeted therapies. For example, about 12 percent of patients had rearrangements involving the genes ABL1, ABL2, CSF1R and PDGFRB, which are known to respond to dasatnib and related TKIs.
Numerous other Ph-like ALL patients had gene rearrangements involving JAK2, EPOR and other genes that can be targeted by the drug ruxolitinib. Approved for use against a bone marrow disorder, ruxolitinib is being studied for treatment of a variety of cancers.
The research was part of the Pediatric Cancer Genome Project, a collaboration of St. Jude and Washington University School of Medicine in St. Louis that uses next-generation genome sequencing technology to improve understanding and treatment of some of the most aggressive and least understood childhood cancers. The complete normal and tumor genomes of 700 young cancer patients have been sequenced as a result of the project, which began in 2010.
The study was also part of the National Cancer Institute’s (NCI) Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Initiative. That effort uses genomics to identify therapeutic targets and spur development of more effective treatment for childhood cancer. The NCI is part of the National Institutes of Health (NIH). Study collaborators include St. Jude, COG, the Eastern Cooperative Oncology Group, the Alliance – Cancer and Leukemia Group B and MD Anderson Cancer Center.
The other study authors are Debbie Payne-Turner, Yung-Li Yang, Deqing Pei, Kelly McCastlain, Guangchun Song, Jing Ma, Jared Becksfort, Michael Rusch, John Easton, Jinjun Cheng, Kristy Boggs, Ilaria Iacobucci, Ji Wen, Marcus Valentine, Cheng Cheng, Steven Paugh, Erin Hedlund, Pankaj Gupta, Panduka Nagahawatte, Gang Wu, Xiang Chen, Donald Yergeau, Bhavin Vadodaria, Heather Mulder, Ching-Hon Pui, Sima Jeha, Mary Relling, William Evans, James Downing and Jinghui Zhang, all of St. Jude; Shann-Ching Chen and Natalia Santiago-Morales, both formerly of St. Jude; Richard Harvey, I-Ming Chen and Cheryl Willman, all of the University of New Mexico Cancer Research and Treatment Center, Albuquerque, N.M.; Li Ding, Charles Lu, Robert Fulton, Elaine Mardis and Richard Wilson, all of Washington University, St. Louis; Meenakshi Devidas, University of Florida College of Medicine, Gainesville, Fla.; Shalini Reshmi, Amy Smith and Julie Gastier-Foster, all of Nationwide Children’s Hospital, Columbus; Naomi Winick, University of Texas Southwestern Medical Center, Dallas; Eric Larsen, Maine Children’s Cancer Program, Scarborough, Maine; William Carroll, New York University Cancer Institute, New York; Nyla Heerema, Guido Marcucci, Clara Bloomfield and Krzysztof Mrozek, all of Ohio State University, Columbus, Ohio; Andrew Carroll, University of Alabama at Birmingham; Guy Grayson, Texas A&M Health Science Center, Temple; Sarah Tasian, Children’s Hospital of Philadelphia; Andrew Moore, University of Queensland and Royal Children’s Hospital Brisbane, Australia; Frank Keller, Emory University School of Medicine, Atlanta; Melissa Frei-Jones, University of Texas Health Science Center, San Antonio; James Whitlock, University of Toronto, Canada; Elizabeth Raetz, University of Utah, Salt Lake City; Deborah White and Timothy Hughes, both of South Australian Health and Medical Research Institute, Adelaide, Australia; Jamie Guidry Auvil, Malcolm Smith and Daniela Gerhard, all of NCI, Bethesda, Md.; Jessica Kohlschmidt, of Ohio State and Mayo Clinic, Rochester, Minn.; Wendy Stock, University of Chicago; Steven Kornblau and Marina Konopleva, both of University of Texas MD Anderson Cancer Center, Houston; Elisabeth Paietta, Albert Einstein College of Medicine, Bronx, N.Y.; and Mignon Loh, University of California, San Francisco.
The research was funded in part by the Pediatric Cancer Genome Project, including Kay Jewelers, a lead sponsor; grants (CA21765, CA15793701, CA141762, CA36401, CA114737, CA21115, CA14958, CA101140, CA145707, CA98543, CA98413, CA114766) from NCI; Stand Up to Cancer; St. Baldrick’s Foundation; The Leukemia & Lymphoma Society; Alex’s Lemonade Stand Foundation; a grant (GM92666) from the National Institute of General Medical Sciences at the NIH; and ALSAC.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. St. Jude is ranked the No. 1 pediatric cancer hospital by U.S. News & World Report. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.
Children’s Oncology Group
The Children’s Oncology Group (www.childrensoncologygroup.org) is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. The Children’s Oncology Group (COG) unites more than 8,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and parts of Europe in the fight against childhood cancer. Today, more than 90% of the 13,500 children and adolescents diagnosed with cancer each year in the United States are cared for at COG member institutions. Research performed by the Children’s Oncology Group institutions over the past fifty years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 80%. COG’s mission is to improve the cure rate and outcome for all children with cancer.